Table 1.
Summary of CYP2C8 substrates.
| Specific drugs | Drug class | Treatment indication | Other CYP enzymes that play a role in metabolism |
|---|---|---|---|
| Major contribution of CYP2C8 to metabolism | |||
| All-trans-retinoic acid | Vitamin A derivative | Promyelocytic leukemia | CYP2C9 |
| Amiodarone | Class III antiarrhythmic | Supraventricular and ventricular arrhythmias | CYP3A4, CYP1A2, CYP2C19, CYP2D6 |
| Amodiaquine | 4-aminoquinoline | Malaria | CYP3A4, CYP1A1, CYP1B1 |
| Cerivastatin* | HMG-CoA reductase inhibitor | Hyperlipidemia | CYP3A4 |
| Chloroquine | 4-aminoquinoline | Malaria | CYP3A4, CYP2D6 |
| Paclitaxel | Taxane | Solid malignant tumors (e.g., breast, ovarian, lung) | CYP3A4, CYP3A5 |
| Repaglinide | Meglitinide | Type 2 diabetes | CYP3A4 |
| Rosiglitazone Pioglitazone | Thiazolidinedione | Type 2 diabetes | CYP2C9, CYP3A4 CYP3A4, CYP1A1 |
| Tazarotenic acid | Retinoid derivative | Acne and psoriasis | – |
| Troglitazone* | Thiazolidinedione | Type 2 diabetes | CYP3A4 |
| Intermediate or minor contribution of CYP2C8 to metabolism | |||
| Carbamazepine | Anticonvulsant | Epilepsy | CYP3A4 (major) |
| Cyclophosphamide | Nitrogen mustard alkylating agent | Lymphoma, leukemia, solid tumors | CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP3A |
| Dapsone | Antibacterial sulfone | Leprosy and pneumocystis pneumonia | CYP2C9 (major) |
| Diclofenac | NSAID | Pain and inflammation | CYP2C9 (major), CYP3A4, and CYP2C19 |
| Diltiazem | Calcium channel blocker | Hypertension, arrhythmias, angina | CYP3A4, CYP2C9 |
| Fluvastatin | HMG-CoA reductase inhibitor | Hyperlipidemia | CYP2C9 (major), CYP3A4 |
| Ibuprofen | NSAID | Pain and inflammation | CYP2C9 |
| Ifosfamide | Nitrogen mustard alkylating agent | Various cancers | CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP3A |
| Loperamide | μ-opioid receptor agonist | Antidiarrheal | CYP2B6, CYP2D6, CYP3A4 |
| Methadone | Opioid antagonist | Pain and addiction to opioids | CYP3A4, CYP2D6, CYP2B6 |
| Morphine | Opioid agonist | Pain | CYP3A4 |
| Simvastatin acid | HMG-CoA reductase inhibitor | Hyperlipidemia | CYP3A4 (major) |
| Tenoxicam | NSAID | Pain and inflammation | CYP2C9 (major) |
| Torsemide | Loop diuretic | Edema | CYP2C9 (major) |
| Verapamil | Calcium channel blocker | Hypertension, arrhythmias, angina | CYP3A4 (major), CYP3A5 |
| Zopiclone | Nonbenzodiazepine sedative hypnotic | Insomnia | CYP3A4 (major) |
*
Withdrawn from the market.
This table was adapted and updated from that previously published [1].